NDA 218771 · Almaject
Teriparatide
Teriparatide · Subcutaneous
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 4, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
155
34 Phase 3, 5 recruiting
FAERS reports
7,158
4,980 serious, 406 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TERIPARATIDE · TERIPARATIDE 0.56MG/2.24ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Teriparatide" as an intervention, any sponsor and status, largest first.
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefracturePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05866029 · 2,478 participants (planned) · Start May 26, 2023 · Primary completion Sep 30, 2026
Drug: Denosumab; Teriparatide · For: Osteoporotic Fractures
Sites: Beijing, China; Changchun, China; Changsha, China · 58 sites in all
- Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal WomenPivotal-lookingCompleted
Radius Health, Inc.Industry
NCT01343004 · 2,463 participants · Start Apr 2011 · Primary completion Oct 2014
Drug: Placebo; BA058 80 mcg and 1 more · For: Osteoporosis; Postmenopausal Osteoporosis
Sites: Lakewood, Colorado; Miami, Florida; North Miami, Florida · 28 sites in all
- Effects of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00670501 · 1,637 participants · Start Aug 1996 · Primary completion Apr 1999
Drug: teriparatide; teriparatide and 3 more · For: Osteoporosis, Postmenopausal
Sites: Boston, Massachusetts; Capital Federal, Argentina; Nedlands, Australia · 17 sites in all
- VERtebral Fracture Treatment Comparisons in Osteoporotic WomenPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01709110 · 1,366 participants · Start Oct 2012 · Primary completion Jul 2016
Drug: Teriparatide; Risedronate and 3 more · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Concord, California; Fresno, California · 103 sites in all
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00191425 · 810 participants · Start Aug 2002
Drug: Teriparatide; Raloxifene · For: Osteoporosis, Postmenopausal
Sites: Bad Pyrmont, Germany
- Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by OsteoporosisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00343252 · 712 participants · Start Jun 2006 · Primary completion Jun 2009
Drug: teriparatide; risedronate and 2 more · For: Osteoporosis, Postmenopausal; Back Pain; Spinal Fracture
Sites: Birmingham, Alabama; Montgomery, Alabama; Peoria, Arizona · 72 sites in all
- A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.Pivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT00471237 · 564 participants · Start May 14, 2007 · Primary completion Dec 26, 2008
Drug: Ronacaleret; Teriparatide and 1 more · For: Osteoporosis
Sites: Oakland, California; Palm Desert, California; Walnut Creek, California · 49 sites in all
- To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture RiskPivotal-lookingCompleted
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07028320 · 493 participants · Start Dec 3, 2021 · Primary completion Dec 30, 2023
Drug: SAL056 (56.5μg); Alendronate · For: Postmenopausal Women With Osteoporosis
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness525
- nausea523
- fall503
- fatigue487
- back pain474
- arthralgia461
- device malfunction451
- product dose omission issue433
- pain in extremity425
- pain397
- headache391
- device operational issue360
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 33 |
| 2006 | 16 |
| 2007 | 57 |
| 2008 | 40 |
| 2009 | 52 |
| 2010 | 44 |
| 2011 | 85 |
| 2012 | 307 |
| 2013 | 509 |
| 2014 | 150 |
| 2015 | 142 |
| 2016 | 129 |
| 2017 | 310 |
| 2018 | 437 |
| 2019 | 492 |
| 2020 | 228 |
| 2021 | 185 |
| 2022 | 299 |
| 2023 | 476 |
| 2024 | 986 |
| 2025 | 1,380 |
| 2026 | 791 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Teriparatide (Teriparatide)
2024 spending
$213M
Beneficiaries
15,831
81,093 claims
Per beneficiary
$13,431
$962.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $956,570 |
| 2021 | $24,618,813 |
| 2022 | $62,447,673 |
| 2023 | $89,084,656 |
| 2024 | $212,620,906 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
Khan AA, Morrison A, Hanley DA, et al. · J Bone Miner Res 2015 · Systematic Review, Consensus Statement
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, et al. · JAMA 2016 · Clinical Trial, Phase III, Multicenter Study
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ, Tsai JN, Uihlein AV, et al. · Lancet 2015 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH, Mayer B, Hussein H, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
Li M, Ge Z, Zhang B, et al. · Arch Osteoporos 2024 · Comparative Study, Meta-Analysis
Sponsor: Almaject
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.